KoreaTech Today - Korea's Leading Tech and Startup Media Platform
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government
No Result
View All Result
KoreaTech Today - Korea's Leading Tech and Startup Media Platform
No Result
View All Result
Home Aprinoia Therapeutics

Samsung Biologics, Aprinoia Inks Deal to Develop Alzheimer’s Treatment

 1,329 total views,  1 views today

KoreaTechToday Editor by KoreaTechToday Editor
PUBLISHED: March 17, 2020 UPDATED: March 18, 2020
in Aprinoia Therapeutics, Biotech, China, Samsung Biologics
0
samsung-biologics-plant
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics

Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics

Samsung Biologics announced on Tuesday that it signed a contract with Aprinoia Therapeutics to develop the Taiwan-based biotech firm’s Alzheimer’s disease treatment.

Aprinoia Therapeutics specializes in diagnostic devices and treatments for neurodegenerative diseases. The bioventure is a pioneer and leader in the development of monoclonal antibodies against the tau protein.

aprinoia-therapeutics-logo
Taiwanese biotech firm Aprinoia Therapeutics

The South Korean biotech firm aims to expand its presence in Taiwan and China with the newly forged partnership. Samsung’s affiliate signed a contract development organization (CDO) deal with Aprinoia Therapeutics to jointly develop an anti-tau monoclonal antibody drug candidate, designed to slow the progression of Alzheimer’s disease.

The tau protein binds and stabilizes the brain cells’ internal structures. For Alzheimer’s patients, however, those tau proteins instead tend to stick to each other, disrupting the healthy brain system.

Samsung Biologics through a statement said that the partnership with Aprinoia covers the full scope of the candidate product’s development phase from cell line development, process development, current Good Manufacturing Practice (cGMP) manufacturing to an investigational new drug (IND) filing support.

Through the CDO, Samsung Biologics would manufacture a clinical sample of the Taiwanese company’s Alzheimer’s treatment pipeline. It would also aid in its application for clinical tests as investigational novel drug.

Kim Tae-han, Samsung Biologics CEO, expressed their excitement over the opportunity to partner with a biotech company with a distinguished global presence amidst the fast-growing bio landscape in Asia. The Korean company looks forward to demonstrating its unique capabilities, scale, and integrated CDO and leading contract manufacturing organization (CMO) services to their valued clients, he added.

CDO

The CDO would help Samsung biologics to effectively boost its portfolio covering mainland China as well as Taiwan. The Samsung affiliate is already in talks with around 20 Chinese biotech companies for additional business agreements.

Samsung Biologics recently injected more resources to promote its CDO business. The company expects the business to grow 15 percent annually over the following years.

Established in 2011, the biotech firm has grown into one of the leading contract-based drugs making companies. It has since carried out 48 CDO projects, which helps venture companies in the biotechnology sector conduct drug development.

What’s your thoughts?
+1
0
Upvote
+1
0
Clap
+1
0
Clap
+1
0
On fire
+1
0
Meh
+1
0
Clap
+1
0
Tags: Alzheimer's diseaseAprinoia TherapeuticsbiotechCDOSamsung Biologicstau proteintreatment

Related Posts

SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Battery

SK Innovation Signs a Deal With Chinese EV Market Player for Battery Supply

September 9, 2021
Samsung Biologics partners with Moderna in a large-scale, fill-finish manufacturing deal, boosting the global supply of vaccines against COVID-19.
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Healthcare

Samsung Biologics Boosts Global COVID-19 Vaccine Supply with Moderna

May 24, 2021
The Com2us mobile game, "Summoners War: Sky Arena," received approval from China 's National Press and Publication Administration. /photo taken from Com2us website
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
China

China Grants Approval of Com2us Korean Game for First Time in 4 Years

December 8, 2020
President Moon Jae-in giving a speech about the country's biotechnology industry during a signing ceremony held at Yonsei University Global Campus in Songdo, Incheon.
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Biotech

South Korean Firms to Inject 10 Trillion Won into Biotechnology by 2023

November 19, 2020
Samsung Biologics delivers first batch of Eli Lilly's COVID-19 antibody treatment.
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
Coronavirus

Samsung Biologics to Manufacture Eli Lilly‘s COVID-19 Antibody Treatment

November 19, 2020
LG Display provides first transparent OLED displays for windows used on China’s subway trains.
Samsung Biologics partners with Aprinoia Therapeutics to develop Alzheimer's disease treatment. Photo shows Samsung Biologics' plant located in Songdo, Incheon. / photo courtesy of Samsung Biologics
China

LG Display Supplies Transparent OLED Screen to China’s Subway

August 21, 2020
No Result
View All Result

Follow Us

FREE NEWSLETTER




PRODUCTS

Most Popular

  • 5 Best Korean to English Translation Apps

    0 shares
    Share 0 Tweet 0
  • Top South Korean Tech Products to Look Out for in 2021

    0 shares
    Share 0 Tweet 0
  • 5 All-Time Best Rom-Com K-Dramas to Watch

    0 shares
    Share 0 Tweet 0
  • Top Nine Mobile MMORPG in South Korea for 2020

    0 shares
    Share 0 Tweet 0
  • Best Korean Dramas To Watch This 2021

    0 shares
    Share 0 Tweet 0
  • Coway Changes Name After Netmarble’s Aquisition

    0 shares
    Share 0 Tweet 0
  • Top 8 South Korean Mobile MMORPG to Watch Out For in 2021

    0 shares
    Share 0 Tweet 0
  • SKT Popularizes Social VR with Ifland Metaverse Platform

    0 shares
    Share 0 Tweet 0
  • LG, Samsung to Reveal Advanced AI-Based Fridges at CES 2020

    0 shares
    Share 0 Tweet 0
  • Naver Cloud & Samsung Electronics to build the world’s first 5G driven cloud-based autonomous driving robot 

    0 shares
    Share 0 Tweet 0
  • About Us
  • Account Page
  • application form
  • Cookie policy
  • Default Redirect Page
  • homepage
  • Login
  • login form
  • LogOut
  • Newsletter
  • Privacy Policy
  • Register
  • Reset Password
  • Sample Page
  • Subscription Plan
  • Terms of Use
  • test
  • test
  • testpage
  • TOS Page
  • Visitor Inside User Page

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |

No Result
View All Result
  • Topics
    • Naver
    • Kakao
    • Nexon
    • Netmarble
    • NCsoft
    • Samsung
    • Hyundai
    • SKT
    • LG
    • KT
    • Retail
    • Startup
    • Blockchain
    • government

Copyright © 2021 KoreaTechToday | About Us | Terms of Use |Privacy Policy |Cookie Policy|Contact : [email protected] |